FDA Green Lights Ketamine for Treatment of ALS
“This designation not only expedites our regulatory, clinical, and product development plans but also validates our belief in the potential of ketamine,” says PharmaTher CEO Fabio Chianelli.
Author: Emily Jarvie
Mindset Pharma Files Patent for Quickest, Cheapest Method to Synthesize Psilocybin
“Based on our research, we think we’re able to get to psilocybin in fewer steps than any of the other published methods,” says the company’s CEO.
Australia’s First Psychedelic Research Institute Opens with $40 Million Investment
Psychae Institute will collaborate with other clinical research organizations to develop novel psychedelic medicines and accompanying psychotherapeutic treatment models.
TheraPsil’s Fight to Secure Therapeutic Psilocybin Access for All Canadians
CEO Spencer Hawkswell calls current exemptions for terminally ill under Section 56 of Canada’s Controlled Drugs and Substances Act a “half-assed solution,” and is lobbying for more.
Psychedelic Companies HAVN Life Sciences, MINDCURE Health Reach Manufacturing Milestones
The global supply chain of regulated psilocybin and ibogaine continues to grow as these Canadian companies beef up manufacturing efforts.
Akome Biotech Patents Psychedelic Drug Formulation to Treat Parkinson’s Disease
There is currently no known cure for the disease affecting 10 million people worldwide, but this psychedelics company thinks it has found a “viable candidate” using DMT.
Cybin Receives Conditional Approval to Trade on NYSE American
And in other psychedelic stock news, Origin Therapeutics launches to make equity investments in emerging psychedelics-related companies.
Wake Network Partners with Lieber Institute to Develop Genetics-Based Screening System for Psychedelic Therapies
Fungi bioscience company describes the project as “one of the most robust genetics research initiatives in the emerging psychedelics space to date.”
Free Ketamine Treatment Now Available for Canadian Veterans
Medavie Blue Cross partners with medical research company Braxia Scientific to cover ketamine care for veterans at Canadian Rapid Treatment Centres of Excellence.
Third Psychedelic Stock ETF Coming Soon, Core One Labs Prepares to List on NASDAQ
Advisorshares Plant Medicine ETF will be listed on the NYSE Arca under the symbol PSIL.
End of content
End of content